Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/33627
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGENEROSO, Giuliano
dc.contributor.authorJANOVSKY, Carolina C. P. S.
dc.contributor.authorBITTENCOURT, Marcio S.
dc.date.accessioned2019-09-23T14:22:14Z-
dc.date.available2019-09-23T14:22:14Z-
dc.date.issued2019
dc.identifier.citationCURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, v.26, n.2, p.109-116, 2019
dc.identifier.issn1752-296X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/33627-
dc.description.abstractPurpose of review In this review, we intend to show the heterogenicity of the triglyceride group, including the triglyceride-rich lipoproteins and its subparticles, apolipoproteins, and its role in atherogenesis through epidemiological and genetic studies, observing the association of these various components and subclasses with subclinical atherosclerosis and cardiovascular events. Also, we reevaluated the moment of blood collection for the triglyceride measurement and its repercussion in atherosclerosis. Finally, we present the current scenario and new insights about the pharmacologic treatment of hypertriglyceridemia. Recent findings Recent studies have been observed, a correlation between cardiovascular disease and triglyceride components (as apolipoproteins A-V, C-I, C-III) as well as proteins involved in the metabolism pathway, such as the angiopoietin-like proteins. Also, the triglyceride-rich lipoproteins, also known as remnants, were recently associated with atherogenesis. Another important topic addressed is about nonfasting triglyceride level, which has been postulated as a better predictor of cardiovascular events than fasting collection. Summary Regarding hypertriglyceridemia treatment, the drug therapy was updated, as the omega-3 polyunsaturated fatty acids were tested in primary prevention as eicosapentaenoic acid and docosahexaenoic acid combination resulted in no benefit, whereas the administration of icosapent ethyl in secondary prevention and high-risk patients showed a robust decrease of the cardiovascular outcomes.eng
dc.description.sponsorshipSanofi
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofCurrent Opinion in Endocrinology Diabetes and Obesity
dc.rightsrestrictedAccesseng
dc.subjectnonfasting triglycerideseng
dc.subjectomega-3eng
dc.subjecttriglyceride-rich lipoproteineng
dc.subjecttriglycerideseng
dc.subject.otherlow-density lipoproteinseng
dc.subject.othernuclear-magnetic-resonanceeng
dc.subject.othercoronary-artery-diseaseeng
dc.subject.otherof-function mutationseng
dc.subject.othervery-low-densityeng
dc.subject.otherserum apolipoprotein b-48eng
dc.subject.otherintima-media thicknesseng
dc.subject.otherinsulin-resistanceeng
dc.subject.otherplasma triglycerideeng
dc.subject.othernonfasting triglycerideseng
dc.titleTriglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosiseng
dc.typearticleeng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.identifier.doi10.1097/MED.0000000000000468
dc.identifier.pmid30694827
dc.subject.wosEndocrinology & Metabolismeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.description.beginpage109
hcfmusp.description.endpage116
hcfmusp.description.issue2
hcfmusp.description.volume26
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000480679200007
hcfmusp.origem.id2-s2.0-85071133402
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAbd Alamir M, 2018, J LIPIDS, V2018, P1eng
hcfmusp.relation.referenceAmor AJ, 2016, ATHEROSCLEROSIS, V247, P161, DOI 10.1016/j.atherosclerosis.2016.02.014eng
hcfmusp.relation.referenceAneni EC, 2019, J ATHEROSCLER THROMB, V26, P50, DOI 10.5551/jat.40741eng
hcfmusp.relation.referenceAustin MA, 1998, AM J CARDIOL, V81, p7B, DOI 10.1016/S0002-9149(98)00031-9eng
hcfmusp.relation.referenceBansal S, 2007, JAMA-J AM MED ASSOC, V298, P309, DOI 10.1001/jama.298.3.309eng
hcfmusp.relation.referenceBasu A, 2016, DATA BRIEF, V6, P33, DOI 10.1016/j.dib.2015.11.036eng
hcfmusp.relation.referenceBhatt DL, 2019, NEW ENGL J MED, V380, P11, DOI 10.1056/NEJMoa1812792eng
hcfmusp.relation.referenceBittencourt MS, 2017, AM J CARDIOL, V119, P1352, DOI 10.1016/j.amjcard.2017.01.033eng
hcfmusp.relation.referenceBjorkegren J, 2000, CIRCULATION, V101, P227, DOI 10.1161/01.CIR.101.3.227eng
hcfmusp.relation.referenceBjorkegren J, 1999, ATHEROSCLEROSIS, V144, P124, DOI 10.1016/S0021-9150(99)80484-5eng
hcfmusp.relation.referenceCASLAKE MJ, 1992, EUR J CLIN INVEST, V22, P96, DOI 10.1111/j.1365-2362.1992.tb01942.xeng
hcfmusp.relation.referenceCRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702eng
hcfmusp.relation.referenceCrosby J, 2014, NEW ENGL J MED, V371, P22, DOI 10.1056/NEJMoa1307095eng
hcfmusp.relation.referenceDACHET C, 1995, ATHEROSCLEROSIS, V113, P1, DOI 10.1016/0021-9150(94)05411-Beng
hcfmusp.relation.referenceDi Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619eng
hcfmusp.relation.referenceDo R, 2015, NATURE, V518, P102, DOI 10.1038/nature13917eng
hcfmusp.relation.referenceFesta A, 2005, CIRCULATION, V111, P3465, DOI 10.1161/CIRCULATIONAHA.104.512079eng
hcfmusp.relation.referenceFRY DL, 1992, ARTERIOSCLER THROMB, V12, P1313, DOI 10.1161/01.ATV.12.11.1313eng
hcfmusp.relation.referenceGarvey WT, 2003, DIABETES, V52, P453, DOI 10.2337/diabetes.52.2.453eng
hcfmusp.relation.referenceGoff DC, 2005, METABOLISM, V54, P264, DOI 10.1016/j.metabol.2004.09.002eng
hcfmusp.relation.referenceGouni-Berthold I, 2017, J CLIN LIPIDOL, V11, P794eng
hcfmusp.relation.referenceGraham MJ, 2017, NEW ENGL J MED, V377, P222, DOI 10.1056/NEJMoa1701329eng
hcfmusp.relation.referenceGuo QS, 2005, METABOLISM, V54, P689, DOI 10.1016/j.metabol.2004.12.014eng
hcfmusp.relation.referenceGUYTON JR, 1989, AM J PATHOL, V134, P705eng
hcfmusp.relation.referenceGuyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4eng
hcfmusp.relation.referenceHamsten A, 2005, J AM COLL CARDIOL, V45, P1013, DOI 10.1016/j.jacc.2004.12.049eng
hcfmusp.relation.referenceHayashi T, 2008, ATHEROSCLEROSIS, V197, P154, DOI 10.1016/j.atherosclerosis.2007.03.015eng
hcfmusp.relation.referenceHodge AM, 2009, DIABETES RES CLIN PR, V83, P132, DOI 10.1016/j.diabres.2008.11.007eng
hcfmusp.relation.referenceHodson L, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002258eng
hcfmusp.relation.referenceHokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014eng
hcfmusp.relation.referenceHULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503eng
hcfmusp.relation.referenceJakob T, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009753.pub2eng
hcfmusp.relation.referenceJorgensen AB, 2014, NEW ENGL J MED, V371, P32, DOI 10.1056/NEJMoa1308027eng
hcfmusp.relation.referenceKawakami A, 2001, HORM METAB RES, V33, P67, DOI 10.1055/s-2001-12397eng
hcfmusp.relation.referenceKinoshita M, 2009, J ATHEROSCLER THROMB, V16, P517, DOI 10.5551/jat.No604eng
hcfmusp.relation.referenceLucero D, 2016, CLIN BIOCHEM, V49, P932, DOI 10.1016/j.clinbiochem.2016.04.016eng
hcfmusp.relation.referenceLyons T, 2000, DIABETES RES CLIN PR, V50, P5eng
hcfmusp.relation.referenceMackey RH, 2015, DIABETES CARE, V38, P628, DOI 10.2337/dc14-0645eng
hcfmusp.relation.referenceManson JE, 2019, NEW ENGL J MED, V380, P23, DOI 10.1056/NEJMoa1811403eng
hcfmusp.relation.referenceMarshall WJ, 2014, CLIN BIOCH METABOLICeng
hcfmusp.relation.referenceMasuda D, 2017, J ATHEROSCLER THROMB, V24, P95, DOI 10.5551/jat.RV16003eng
hcfmusp.relation.referenceMasuda D, 2012, EUR J CLIN INVEST, V42, P992, DOI 10.1111/j.1365-2362.2012.02687.xeng
hcfmusp.relation.referenceMiller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726eng
hcfmusp.relation.referenceMittendorfer B, 2016, J CLIN ENDOCR METAB, V101, P4151, DOI 10.1210/jc.2016-1500eng
hcfmusp.relation.referenceMora S, 2010, DIABETES, V59, P1153, DOI 10.2337/db09-1114eng
hcfmusp.relation.referenceMori K, 2013, CLIN CHIM ACTA, V421, P51, DOI 10.1016/j.cca.2013.02.005eng
hcfmusp.relation.referenceNatarajan P, 2015, J AM COLL CARDIOL, V66, P2053, DOI 10.1016/j.jacc.2015.08.866eng
hcfmusp.relation.referenceNORDESTGAARD BG, 1992, ARTERIOSCLER THROMB, V12, P6, DOI 10.1161/01.ATV.12.1.6eng
hcfmusp.relation.referenceNORDESTGAARD BG, 1992, EUR J EPIDEMIOL, V8, P92, DOI 10.1007/BF00145358eng
hcfmusp.relation.referenceNORDESTGAARD BG, 1988, J LIPID RES, V29, P1491eng
hcfmusp.relation.referenceNORDESTGAARD BG, 1988, ARTERIOSCLEROSIS, V8, P421, DOI 10.1161/01.ATV.8.4.421eng
hcfmusp.relation.referenceNORDESTGAARD BG, 1990, ARTERIOSCLEROSIS, V10, P477, DOI 10.1161/01.ATV.10.3.477eng
hcfmusp.relation.referenceNordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299eng
hcfmusp.relation.referenceOkubo M, 2014, J ATHEROSCLER THROMB, V21, P974, DOI 10.5551/jat.23309eng
hcfmusp.relation.referenceOoi TC, 1998, CRIT REV CL LAB SCI, V35, P489, DOI 10.1080/10408369891234255eng
hcfmusp.relation.referencePackard CJ, 1997, ARTERIOSCL THROM VAS, V17, P3542, DOI 10.1161/01.ATV.17.12.3542eng
hcfmusp.relation.referencePACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644eng
hcfmusp.relation.referenceParamsothy P, 2010, J AM COLL CARDIOL, V56, P1034, DOI 10.1016/j.jacc.2010.01.073eng
hcfmusp.relation.referencePollin TI, 2008, SCIENCE, V322, P1702, DOI 10.1126/science.1161524eng
hcfmusp.relation.referencePuri R, 2016, ARTERIOSCL THROM VAS, V36, P2220, DOI 10.1161/ATVBAHA.116.307601eng
hcfmusp.relation.referenceQamar A, 2015, ARTERIOSCL THROM VAS, V35, P1880, DOI 10.1161/ATVBAHA.115.305415eng
hcfmusp.relation.referenceRamms B, 2018, CURR OPIN LIPIDOL, V29, P171, DOI 10.1097/MOL.0000000000000502eng
hcfmusp.relation.referenceSarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793eng
hcfmusp.relation.referenceSarwar N, 2010, LANCET, V375, P1634, DOI 10.1016/S0140-6736(10)60545-4eng
hcfmusp.relation.referenceSHAIKH M, 1991, ARTERIOSCLER THROMB, V11, P569, DOI 10.1161/01.ATV.11.3.569eng
hcfmusp.relation.referenceSHEPHERD J, 1984, J CLIN INVEST, V74, P2164, DOI 10.1172/JCI111643eng
hcfmusp.relation.referenceSparks JD, 2012, ARTERIOSCL THROM VAS, V32, P2104, DOI 10.1161/ATVBAHA.111.241463eng
hcfmusp.relation.referenceStaniak HL, 2014, ATHEROSCLEROSIS, V233, P381, DOI 10.1016/j.atherosclerosis.2013.12.036eng
hcfmusp.relation.referenceSTENDER S, 1981, ARTERIOSCLEROSIS, V1, P38, DOI 10.1161/01.ATV.1.1.38eng
hcfmusp.relation.referenceSTENDER S, 1988, ARTERIOSCLEROSIS, V8, P252, DOI 10.1161/01.ATV.8.3.252eng
hcfmusp.relation.referenceStitziel NO, 2017, J AM COLL CARDIOL, V69, P2054, DOI 10.1016/j.jacc.2017.02.030eng
hcfmusp.relation.referenceStitziel NO, 2016, NEW ENGL J MED, V374, P1134, DOI 10.1056/NEJMoa1507652eng
hcfmusp.relation.referenceTalmud PJ, 2008, ARTERIOSCL THROM VAS, V28, P2319, DOI 10.1161/ATVBAHA.108.176917eng
hcfmusp.relation.referenceTang YB, 2006, ATHEROSCLEROSIS, V185, P433, DOI 10.1016/j.atherosclerosis.2005.06.026eng
hcfmusp.relation.referenceToth PP, 2016, VASC HEALTH RISK MAN, V12, DOI 10.2147/VHRM.S104369eng
hcfmusp.relation.referenceTsao CW, 2012, J AM COLL CARDIOL, V60, P2364, DOI 10.1016/j.jacc.2012.09.007eng
hcfmusp.relation.referenceUchida Y, 1998, J CLIN LAB ANAL, V12, P289, DOI 10.1002/(SICI)1098-2825(1998)12:5<289::AID-JCLA7>3.0.CO;2-1eng
hcfmusp.relation.referenceVallejo-Vaz AJ, 2018, CIRCULATION, V138, P770, DOI 10.1161/CIRCULATIONAHA.117.032318eng
hcfmusp.relation.referenceVarbo A, 2018, ARTERIOSCL THROM VAS, V38, P464, DOI 10.1161/ATVBAHA.117.310269eng
hcfmusp.relation.referenceVarbo A, 2013, J AM COLL CARDIOL, V61, P427, DOI 10.1016/j.jacc.2012.08.1026eng
hcfmusp.relation.referencevon Ballmoos MCW, 2015, J CLIN LIPIDOL, V9, P498, DOI 10.1016/j.jacl.2015.05.002eng
hcfmusp.relation.referenceWang D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009580.pub2eng
hcfmusp.relation.referenceWang F, 2018, ANN HUM GENET, V82, P437, DOI 10.1111/ahg.12273eng
hcfmusp.relation.referenceWang J, 2012, J INTERN MED, V272, P562, DOI 10.1111/j.1365-2796.2012.02562.xeng
hcfmusp.relation.referenceZheng TP, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0687-yeng
dc.description.indexMEDLINEeng
dc.identifier.eissn1752-2978
hcfmusp.citation.scopus16-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - HU
Hospital Universitário - HU

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_GENEROSO_Triglycerides_and_triglyceriderich_lipoproteins_in_the_development_and_2019.PDF
  Restricted Access
publishedVersion (English)278.69 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.